PRIADEL

This brand name is authorized in Ireland, Netherlands, New Zealand, United Kingdom

Active ingredients

The drug PRIADEL contains one active pharmaceutical ingredient (API):

1 Lithium UNII 2BMD2GNA4V - LITHIUM CARBONATE

Little is known about the way the lithium ion can modify neurotransmission within the CNS. Many of the proposed mechanisms have suggested an inhibitory effect on components of various neurotransmitter signalling pathways, such as cyclic AMP formation, cyclic GMP formation, G-proteins or inositol phosphate metabolism. Read about Lithium

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PRIADEL Prolonged-release tablet	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05AN01	Lithium	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AN Lithium
Discover more medicines within N05AN01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 27545, 27550, 38331
Country: IE	Health Products Regulatory Authority	Identifier(s): 42242, 42277
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 8621
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 1194